What is CraniUS?
CraniUS Therapeutics operates at the intersection of advanced neurotechnology and medical device engineering. The company is primarily recognized for its flagship implantable platform, NeuroPASS, which represents a significant technical breakthrough in therapeutic delivery. By engineering systems capable of bypassing the blood-brain barrier, CraniUS addresses a critical unmet need in the treatment of high-acuity conditions, including malignant brain tumors, Alzheimer disease, and Parkinson disease. This specialized focus on direct-to-brain drug delivery positions the firm as a high-value player in the neuro-oncology and neurodegenerative disease markets, where traditional systemic therapies often fail to achieve therapeutic efficacy due to physiological barriers.
How much funding has CraniUS raised?
CraniUS has raised a total of $39.4M across 2 funding rounds:
Series A
$19.4M
Series B
$20M
Series A (2022): $19.4M, investors not publicly disclosed
Series B (2026): $20M led by State of Maryland
Key Investors in CraniUS
State of Maryland
The Maryland Department of Health Developmental Disabilities Administration is a state agency focused on providing community services and resources for individuals with intellectual and developmental disabilities through Medicaid waiver programs and state-funded initiatives.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for CraniUS?
Following this major enterprise-level funding, CraniUS is expected to prioritize the expansion of its clinical trial infrastructure and the refinement of its NeuroPASS delivery system. The strategic allocation of capital will likely support regulatory engagement and the scaling of manufacturing capabilities required for late-stage clinical validation. As the company transitions from early-stage development to a more mature operational phase, the focus will shift toward establishing long-term clinical efficacy data and securing the necessary partnerships to facilitate commercialization. This trajectory suggests a robust outlook for the firm as it seeks to translate its innovative neuro-implant technology into a viable, scalable solution for patients suffering from previously intractable neurological conditions.
See full CraniUS company page
